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Résumé en
anglais
Aerosol drug delivery permits the development of dose-intensification strategies in
severe, malignant lung diseases. The aim of the study was to demonstrate that the
encapsulation of paclitaxel in lipid nanocapsules (LNCs), a novel drug nanocarrier
for lipophilic components, allows one to provide pulmonary drug delivery of
paclitaxel by nebulisation, thereby allowing preclinical and clinical studies. LNC
dispersions are made into aerosols with commercial nebulisers. The structure, drug
payload and cytotoxicity of nebulised LNCs were compared to fresh LNCs. The
results demonstrated that LNC dispersions could be made into aerosols by using
mesh nebulisers without altering the LNC structure. Only eFlow® rapid-produced
aerosols are compatible with human use: the mean duration to nebulise 3 ml of LNC
dispersion is less than 9 min, with an aerosol mass median aerodynamic diameter
equal to 2.7 ± 0.1 μm and a fine-particle fraction (between 1.0 and 5.0 μm) of 81.5
± 3.1%. No modifications of drug payload or cytotoxicity effects of paclitaxel-loaded
LNC (PTX–LNC) were observed. In order to carry out preclinical studies, a scaled-up
LNC formulation protocol was used. Chemical parameters, such as acidity and
osmolarity, were optimised, and a storage procedure for PTX–LNC batches was set-
up. Animal studies are now needed to determine the tolerance and therapeutic
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